Takeda Pharmaceutical Company Limited American Depositary Shares (Each Representing 1/2 Of A Share Of Common Stock) (TAK) closed at $20.27 on October 27, 2026, down 0.8% from the previous close, on volume of 2,068,800 shares (30-day average 2,603,669).
Data as of October 27, 2026.
27-Oct-2026
AstraZeneca stomach cancer drug doubles survival in late-stage trial
Seeking Alpha News (Sun, 25-Oct 12:17 PM ET)
Business Wire (Fri, 23-Oct 7:30 AM ET)
Business Wire (Mon, 19-Oct 5:30 AM ET)
Market Chameleon (Thu, 15-Oct 3:38 AM ET)
Business Wire (Wed, 14-Oct 8:30 PM ET)
Business Wire (Wed, 14-Oct 8:00 AM ET)
Business Wire (Wed, 30-Sep 1:00 AM ET)
Business Wire (Tue, 22-Sep 9:30 AM ET)
Business Wire (Fri, 18-Sep 1:00 AM ET)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
Takeda Pharmaceutical Company Limited American Depositary Shares (Each Representing 1/2 Of A Share Of Common Stock) trades on the NYSE stock market under the symbol TAK.
As of October 27, 2026, TAK stock price declined to $20.27 with 2,068,800 million shares trading.
TAK has a beta of -0.01, meaning it tends to be less sensitive to market movements. TAK has a correlation of 0.00 to the broad based SPY ETF.
TAK has a market cap of $64.73 billion. This is considered a Large Cap stock.
Last quarter Takeda Pharmaceutical Company Limited American Depositary Shares (Each Representing 1/2 Of A Share Of Common Stock) reported $8 billion in Revenue and $.48 earnings per share. This beat revenue expectation by $595 million and exceeded earnings estimates by $.09.
In the last 3 years, TAK traded as high as $20.55 and as low as $12.58.
The top ETF exchange traded funds that TAK belongs to (by Net Assets): FVD, PPH, AVDE, APIE, VEU.
TAK has outperformed the market in the last year with a price return of +43.0% while the SPY ETF gained +13.4%. TAK has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +16.2% and +9.4%, respectively, while the SPY returned +4.4% and -1.1%, respectively.
TAK support price is $20.15 and resistance is $20.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TAK shares will trade within this expected range on the day.